Co-Diagnostics Positions PCR Platform for Potential Plague Detection Amid Russia Lab Incident
Event summary
- Co-Diagnostics highlighted its PCR Pro platform's potential for plague diagnostics following the October 2 death of a Russian lab worker, which raised concerns about pneumonic plague.
- The WHO reported on October 10 that no plague or high-threat pathogens were identified, but the cause of death remains undetermined.
- Co-Dx's sputum sample-preparation technology, developed for tuberculosis, could be adapted for plague detection if needed.
- The company is collaborating with ReadyGo Diagnostics to evaluate sample-preparation technology for decentralized Ebola detection.
- Co-Dx has invested in assay development and manufacturing infrastructure, including in-house production of Co-Primers technology in the U.S. and India.
The big picture
Co-Diagnostics is leveraging its experience in rapid response to infectious disease threats, building on its work with COVID-19, mpox, and Ebola. The company's integrated platform, combining proprietary Co-Primers technology and sample-preparation capabilities, positions it to address emerging public health challenges. The recent incident in Russia underscores the need for agile diagnostic solutions in decentralized settings, particularly where access to centralized laboratories is limited.
What we're watching
- Regulatory Pathways
- The pace at which Co-Dx can obtain regulatory authorization for a plague-specific test, should it decide to develop one.
- Technical Feasibility
- Whether the company's sputum sample-preparation methods can be effectively adapted for plague detection.
- Market Demand
- How global health authorities will respond to potential plague outbreaks and the resulting demand for diagnostic solutions.
Related topics
